Regulus Therapeutics Competitors and Similar CompaniesClear all
CureVac's competitors and similar companies include Alnylam.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ||
Founding Date | Founding Date 2000 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | |
Employees | Employees 82517% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 648.3 m | Valuation ($) 36.5 b |
Financial | ||
Revenue (est.) | Revenue (est.) €535.2m (FY, 2024) | Revenue (est.) $3.7b (FY, 2025) |
Cost of goods | Cost of goods €9.7m (FY, 2024) | Cost of goods $677.2m (FY, 2025) |
Gross profit | Gross profit €534.4m (FY, 2024) | Gross profit $3b (FY, 2025) |
Net income | Net income €162.2m (FY, 2024) | Net income $313.7m (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 1.1b | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company